• Fourth Quarter Revenue: $12.2 million, up from $6.1 million in Q4 2023.
• Full Year Revenue: $36.3 million, a 167% increase from $13.6 million in 2023.
• Cost of Product Revenues (Q4): $4.0 million, compared to $1.8 million in Q4 2023.
• Cost of Product Revenues (Full Year): $11.4 million, up from $3.8 million in 2023.
• Research and Development Expenses (Q4): $3.2 million, slightly down from $3.3 million in Q4 2023.
• Research and Development Expenses (Full Year): $12.1 million, up from $11.8 million in 2023.
• Selling, General, and Administrative Expenses (Q4): $21.4 million, up from $16.2 million in Q4 2023.
• Selling, General, and Administrative Expenses (Full Year): $77.6 million, up from $53.4 million in 2023.
• Net Loss (Q4): $18.8 million, compared to $13.8 million in Q4 2023.
• Net Loss (Full Year): $85.1 million, compared to $54.8 million in 2023.
• Cash and Cash Equivalents: $75.7 million as of December 31, 2024.
• Shares Outstanding: 50,095,689 as of December 31, 2024.

• Warning! GuruFocus has detected 5 Warning Signs with SCPH.

Release Date: March 19, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• scPharmaceuticals Inc (NASDAQ:SCPH) reported a significant increase in net revenue for FUROSCIX, with a 167% year-over-year growth, reaching $36.3 million for the full year 2024.
• The company successfully expanded its market reach, particularly in the Class IV heart failure patient population, and increased its commercial sales force, contributing to higher market penetration.
• The FDA approved a supplemental new drug application for FUROSCIX, expanding its indication to include the treatment of edema in patients with chronic kidney disease (CKD), which is expected to be a meaningful growth driver.
• The company has seen positive feedback and performance of FUROSCIX in the market, with over 3,800 unique providers prescribing the medication since its launch.
• scPharmaceuticals Inc (NASDAQ:SCPH) ended 2024 with a strong cash position of $75.7 million, providing a solid financial foundation for future growth initiatives.

Negative Points

• The gross to net discount for FUROSCIX increased to approximately 19% in Q4 2024, with expectations for it to rise to 30%-35% in 2025 due to Medicare redesign impacts.
• scPharmaceuticals Inc (NASDAQ:SCPH) reported a net loss of $18.8 million for Q4 2024 and $85.1 million for the full year, indicating ongoing financial challenges.
• Selling, general, and administrative expenses increased significantly, reaching $21.4 million in Q4 2024, primarily due to higher employee-related costs and commercial preparation expenses.
• The company faces challenges with patient out-of-pocket costs, which have historically impacted FUROSCIX's fill rates and demand.
• There is uncertainty regarding the full impact of the Medicare redesign on the company's financials, making it difficult to provide precise guidance for future revenue growth.

Q & A Highlights

Q: Can you discuss the potential opportunity that the CKD launch represents for FUROSCIX and your expectations for the launch starting in April? A: John Tucker, CEO, explained that the CKD launch presents a significant opportunity due to the overlap with heart failure patients. The company has already engaged with nephrologists and expects a quicker uptake than in cardiology. Steve Parsons, SVP of Commercial, added that nephrologists often treat patients with both CKD and heart failure, making it a concentrated target area. The full launch is expected in mid-April, with revenue impact anticipated mainly in Q3 and Q4.

Q: What hurdles have you faced in achieving the desired adoption rate for FUROSCIX, and what could accelerate the ramp? A: John Tucker, CEO, noted that patient out-of-pocket costs were a significant hurdle last year. With the Medicare redesign reducing the out-of-pocket cap to $2,000 and introducing a smoothing option, they expect improved patient access and increased fill rates. The redesign is seen as a tailwind for 2025, alongside the CKD launch and expanded sales force.

Q: Could you push for more favorable payer coverage for FUROSCIX now that you have two indications? A: Steve Parsons, SVP of Commercial, stated that they are satisfied with their current payer position, especially with the Medicare redesign offering $0 co-pays for patients in catastrophic coverage. They do not plan to change their position as it would be costly and unnecessary given the expected benefits from the redesign.

Q: How will the CKD launch affect your promotional strategy and interaction frequency with healthcare providers? A: John Tucker, CEO, mentioned that while initial efforts in nephrology will require more in-services, they do not expect it to impact the frequency of interactions with cardiologists significantly. The sales force expansion allows for efficient coverage of both specialties, and they are prepared to adjust if needed.

Q: Are you seeing any impact from the Medicare redesign on fill rates and demand for FUROSCIX? A: John Tucker, CEO, confirmed that they have recently observed more patients enrolling in smoothing and experiencing lower co-pays, leading to increased fill rates. While there was initial confusion, the situation is improving, and they expect continued positive impact as more patients reach their out-of-pocket caps.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.